The lung and heart effects of Fumonisins are double:

- enhancement of bronchiolo-alveolar permeation
FUMONISINS: cardio-pulmonary effects
HealthValue
Dihydroceramides
CERAMIDES
(N-acyl sphingosines)
glycosyl ceramides
Sphingosine (Sph)
Spingosine -1 phosphate (S1P)
ceramide
synthases
X
Fumonisin B1 inhibits ceramide synthases
sphingosine kinase
S1P1r
S1P2r
S1P3r
S1P4r
S1P5r
Ceramide driven signaling cascades
are involved in endothelial cell apoptosis (Berdyshev)
v.
v.
v.
v.
v.
Alveolar IL8
(Milara)
<
Lung vascular
leak (Shea)
Activation of
Rho-ROCK-PTEN
(Sanchez, Szczepaniak)
Disruption of adherens junctions
Increased bronchiolo-alveolar
paracellular permeation
v
v
Cardiac effects
v
Chronotropic negative &
Inotropic negative
(Means)
very similar to beta blocker effect
v
Pulmonary artery vasoconstriction, like beta blockers





these elements have been described in many species, including human pulmonary endothelial cells
Lung/heart effects are not species-specific to swine, even if they have drawn more attention in that animal. They are known in horses with experimental leukoencephalomalacia (Smith).
They are not due to left ventricular failure (beta-blockers do not induce pulmonary edema !), but to toxic vascular barrier disruption. If you have any doubt, just show the papers claiming the contrary to a cardio-vascular pharmacologist.
The beta-blocker mimetic effect of Fumonisin B1
Propranolol data from humans : Mueller et al., Circulation, 1974,49: 1078
Fumonisin B1 data from swine: Smith et al., Toxicol. Sci.2000, 56:240
- typical beta-blocker mimetic effect
Pulmonary effects